MARKET

RYTM

RYTM

Rhythm Pharmaceu
NASDAQ
57.28
+0.49
+0.86%
After Hours: 57.28 0 0.00% 16:20 05/14 EDT
OPEN
57.31
PREV CLOSE
56.79
HIGH
58.45
LOW
55.31
VOLUME
666.73K
TURNOVER
--
52 WEEK HIGH
68.58
52 WEEK LOW
35.17
MARKET CAP
3.64B
P/E (TTM)
-20.3474
1D
5D
1M
3M
1Y
5Y
1D
Stifel Nicolaus Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
TipRanks · 15h ago
Rhythm Pharmaceuticals announces presentations on setmelanotide
TipRanks · 15h ago
*Rhythm Pharmaceuticals: New Data Showed Setmelanotide Achieved Consistent, Meaningful Weight Reduction >RYTM
Dow Jones · 15h ago
*Rhythm Pharmaceuticals Announces New Data Presentations On Patients With Acquired Or Congenital Hypothalamic Obesity (N=35) Treated With Setmelanotide For Up To Nine Months In French Early-access Program >RYTM
Dow Jones · 15h ago
Buy Rating Affirmed for Rhythm Pharmaceuticals on Promising Setmelanotide Data and Positive Outlook
TipRanks · 1d ago
Weekly Report: what happened at RYTM last week (0505-0509)?
Weekly Report · 2d ago
Buy Rating for Rhythm Pharmaceuticals Driven by Promising Prospects of IMCIVREE and Expansion into Hypothalamic Obesity
TipRanks · 6d ago
Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals
TipRanks · 6d ago
More
About RYTM
More
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Recently
Symbol
Price
%Change

Webull offers Rhythm Pharmaceuticals Inc stock information, including NASDAQ: RYTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RYTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RYTM stock methods without spending real money on the virtual paper trading platform.